代谢相关脂肪性肝病自然史研究进展

doi:10.3969/j.issn.1672-5069.2023.06.001

Abstract

Zeng Jing, Fan Jiangao. Natural history of metabolic dysfunction-associated fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 769-772.

[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73(1):202-209.
[2] Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol,2023,S0168-8278(23)00418-X.
[3] 范建高,李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志, 2023,31(8):789-792.
[4] Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism,2013,62(3):352-360.
[5] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64(1):73-84.
[6] Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med,2021,385(17):1559-1569.
[7] Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology,2020,71(3):808-819.
[8] Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol,2023,78(3):471-478.
[9] Thomas JA, Kendall BJ, Dalais C, et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer,2022,173:250-262.
[10] Männistö VT, Salomaa V, Färkkilä M, et al. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int,2021,41(11):2590-2600.
[11] Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology,2020,72(5):1605-1616.
[12] Toh JZK, Pan XH, Tay PWL, et al. A Meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2022,20(11):2462-2473,e10.
[13] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2021,6(11):903-913.
[14] Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut,2022,2022-327672.
[15] Tang ASP, Chan KE, Quek J, et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clin Mol Hepatol,2022,28(3):483-496.
[16] Zhang RN, Fan JG. Editorial: opposite effects of genetic polymorphisms known to induce NAFLD on hepatic and cardiovascular outcomes in Chinese population. Aliment Pharmacol Ther,2022,55(7):876-877.
[17] Wang Z, Zhao X, Chen S, et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin Gastroenterol Hepatol,2021,19(4):788-796,e4.
[18] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut,2022,71(4):778-788.
[19] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut,2021,70(5):962-969.
[20] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut,2022,71(1):156-162.
[21] Zou ZY, Fan JG. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. J Hepatol,2020,73(1):214-216.
[22] Ayada I, van Kleef LA, Alferink LJM,et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int,2022,42(2):277-287.
[23] Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology,2022,76(5):1423-1437.
[24] Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol,2021,75(6): 1284-1291.
[25] van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep,2021,3(5):100350.
[26] 顾棨, 芮法娟, 倪文婧, 等. 非酒精性脂肪性肝病的规范化管理. 实用肝脏病杂志,2023,26(4):457-459.
[27] 张淮, 郑明华. MAFLD高危人群的筛查和分层管理. 实用肝脏病杂志,2023,26(4):463-466.
[28] 何方平. 我国NAFLD慢病管理实践现状和建议. 实用肝脏病杂志, 2023,26(4):460-462.

Natural history of metabolic dysfunction-associated fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Shi Yiwen, Fan Jiangao. Epidemiologic status of metabolic dysfunction-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 777-780.
[2]	Zhou Jiying, Xie Yuehong, Yu Cuixia. Decreased biochemical response to entecavir anti-viral therapy in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 793-796.
[3]	Shao Xiaoru, Zhou Xiao, Ge Yingying. Diagnosis of coronary atherosclerotic heart disease in patients with nonalcoholic fatty liver disease by CCTA and¹⁸F-FDG intake [J]. Journal of Practical Hepatology, 2023, 26(6): 811-814.
[4]	Ding Xiaojie, Zhang Yongming, Song Haiyan, et al. Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study [J]. Journal of Practical Hepatology, 2023, 26(6): 815-818.
[5]	Wu Fei, Guo Wen, Zhang Qun. Skeletal muscle mass changes in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(5): 646-649.
[6]	He Fangping. Practice of chronic disease management: What we should do in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 460-462.
[7]	Wang Zhuoya, Wu Yangpeng, Huang Yitao. Observation of polyene phosphatidylcholine and zhibitai capsule combination in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 496-499.
[8]	Yin Huifen, Yu Hongyan, Liu Zhiping. Changes of serum leptin, retinol-binding protein-4 and cholinesterase levels in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2023, 26(4): 500-503.
[9]	Zhao Lingling, Wang Beibei, Yao Yongli, et al.. Serum resistin and triacylglycerol glucose index in patients with T2DM and non-alcoholic fatty liver: their combination for progressive fibrosis [J]. Journal of Practical Hepatology, 2023, 26(3): 356-359.
[10]	Huang Hui, Lin Min, Zeng Guixiang. Hepatic ultrastructural features of paediatric Wilson’s disease, NAFLD and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 364-367.
[11]	Fan Mingfang, Tian Ying, Zhou Qian, et al.. Changes of serum RBP4 and SREBP-1c levels in patients with chronic hepatitis C and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 185-188.
[12]	Fang Ying, Jin Jiadong, Wang Fu, et al.. Impact of COVID-19 pandemic on emotions and liver function tests in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 193-196.
[13]	Li Xiaomeng, Wu Shaoyu, Wang Yuanyuan. Implication of serum homocystein, fibroblast growth factor-21 and nuclear factor-κB levels in patients with non-alcoholic fatty liver diseases and T2DM [J]. Journal of Practical Hepatology, 2023, 26(2): 202-205.
[14]	Huang Danxia, Zhao Zhihui, Xiao Yuexing, et al. Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats [J]. Journal of Practical Hepatology, 2023, 26(1): 23-26.
[15]	Xu Weiqiang, Liu Shuping, Li Xiaomeng. Risk factors of non-alcoholic fatty liver diseases in physical examination individuals [J]. Journal of Practical Hepatology, 2023, 26(1): 35-38.